ANKE BIO(300009)

Search documents
安科生物:关于控股子公司收到安徽省药品监督管理局通知的公告
2024-09-30 13:12
证券代码:300009 证券简称:安科生物 公告编号:2024-047 安徽安科生物工程(集团)股份有限公司 关于控股子公司收到安徽省药品监督管理局通知的公告 本公司及董事会全体成员保证公告内容真实、准确和完整,没有虚假记载、 误导性陈述或者重大遗漏。 一、情况概述 安徽安科生物工程(集团)股份有限公司(以下简称"公司")接到控股子 公司安徽安科余良卿药业有限公司(以下简称"余良卿公司")通知,安徽省药 品监督管理局(以下简称"省药监局")近期对余良卿公司进行了GMP符合性检 查,因余良卿公司存在部分厂房设施、设备陈旧等原因,达不到现行GMP管理 的相关要求,余良卿公司暂停生产。本次暂停生产,不存在要求余良卿公司召回 已销售的相关产品的情形,也不影响库存产品继续销售。 二、公司采取的应对措施 余良卿公司在接到通知后已按要求进行停产整改,公司知悉相关事件后,与 余良卿公司相关负责人核查此事,对该事项高度重视并要求余良卿公司立即制定 整改方案,对现场检查发现的不符合项全面落实整改措施。目前,余良卿公司正 在进行整改工作,预计短期内即可完成整改,并将按要求尽快向省药监局提交复 产检查申请,检查符合要求后即可恢复生产 ...
安科生物:关于第八届董事会第十三次会议决议的公告
2024-09-30 13:08
本公司及董事会全体成员保证公告内容真实、准确和完整,没有虚假记载、 误导性陈述或者重大遗漏。 证券代码:300009 证券简称:安科生物 公告编号:2024-045 安徽安科生物工程(集团)股份有限公司 关于第八届董事会第十三次会议决议的公告 根据《公司第 2 期员工持股计划管理办法》等相关规定,综合考虑证券市场, 基于对公司未来持续稳定发展的信心及公司股票价值的判断,同意将公司第 2 期员工持股计划的存续期延长至 2026 年 3 月 28 日止。 宋礼华先生、周源源女士、宋礼名先生、李坤先生、江军培先生作为关联董 事,在董事会审议本议案时进行了回避表决。 具体内容详见同日刊登在中国证监会指定信息披露网站巨潮资讯网的《关于 延长公司第 2 期员工持股计划存续期的公告》(公告编号:2024-046)。 本议案以7票同意、0票反对、0票弃权获得通过。 特此公告。 安徽安科生物工程(集团)股份有限公司(下称"公司")第八届董事会第 十三次会议于2024年09月30日9:30以现场及通讯会议的方式召开,会议通知于 2024年09月20日以直接、邮件的形式送达。应到董事12人,实到董事12人,公司 全体监事、高级管理 ...
安科生物:对外投资管理制度
2024-09-30 12:34
安徽安科生物工程(集团)股份有限公司 (一)遵守国家法律法规、符合相关产业政策以及《公司章程》的规定; (二)符合公司发展战略、中长期产业规划与业务发展需求,投资项目具有先进 性、合理性和可行性; (三)公司对外投资的内部控制应遵循合法、审慎、安全、有效的原则,注重投 资项目的可行性分析、风险评估与控制,保障公司对外投资资金的保值与增值,保障 公司投入运营资金的安全、高效。 第四条 本制度适用于本公司及本公司的全资、控股子公司(以下简称"子公 司")。公司合营、联营、合资、参股的企业(以下简称"参股公司")进行本制 度所述对外投资事项,可能对公司产生较大影响的,公司应当参照本制度的规定履 安徽安科生物工程(集团)股份有限公司 对外投资管理制度 第一章 总 则 第一条 为了进一步规范安徽安科生物工程(集团)股份有限公司(以下简称"公 司"或"本公司") 对外投资行为,防范对外投资风险,提高公司的盈利能力和抗风 险能力,根据《中华人民共和国公司法》(以下简称"《公司法》")、《深圳证券 交易所创业板股票上市规则》(以下简称"《创业板上市规则》")、《深圳证券交 易所上市公司自律监管指引第2号——创业板上市公司规范 ...
安科生物:关于获得第一类医疗器械备案凭证的公告
2024-09-18 09:11
证券代码:300009 证券简称:安科生物 公告编号:2024-044 Calconuor white(CFW)是一种荧光染料,它与多种植物及真菌胞壁的几丁 质和纤维素有很强的亲和力,在一定的长波紫外光下,被CFW染色的真菌会发 出很强的亮蓝色荧光,主要在皮肤/呼吸科有着广泛的应用。相比于传统的真菌 染色方法,钙荧光白染色液(CFW)有快速检测、对比鲜明的特点,国外实验 室已将其作为从标本中直接检测真菌的一种常用方法。 免疫显色试剂采用荧光染色方法和受光显色原理,对各种临床样本中的脱落 细胞进行染色,供临床辅助参考。 钙荧光白染色液(CFW)和免疫显色试剂的获批,有利于丰富了公司诊断 试剂产品线,在生殖检测市场的基础上横向拓宽到泌尿健康、皮肤及呼吸内科细 分市场,进一步提升了公司的市场综合竞争力,对公司未来的经营将产生积极影 响。 产品的销售受市场因素影响,存在不确定性,敬请投资者谨慎决策,注意投 资风险。 安徽安科生物工程(集团)股份有限公司 关于获得第一类医疗器械备案凭证的公告 本公司及董事会全体成员保证公告内容真实、准确和完整,没有虚假记载、 误导性陈述或者重大遗漏。 安徽安科生物工程(集团)股份有限公 ...
安科生物:新产品开拓有望引领长期增长
Huajing Securities· 2024-09-03 11:08
Investment Rating - The report maintains a "Buy" rating for the company with a target price of RMB 10.78, representing a potential upside of 34% from the current price of RMB 8.02 [1][12]. Core Views - The company is expected to achieve long-term growth driven by the development of new products, particularly in the oncology treatment sector with the launch of its first antibody drug, trastuzumab [4][5]. - The company has a stable revenue growth outlook, with a projected revenue CAGR of 9% and net profit CAGR of 18% for the years 2023-2026, despite a downward adjustment from previous estimates [4][10]. - The report highlights a decrease in R&D expenses by 26.44% in 1H24, which has contributed to stabilizing net profit growth [4][7]. Financial Summary - For 1H24, the company reported revenue of RMB 1.299 billion, a year-on-year increase of 1%, and a net profit of RMB 416 million, up 5% from the previous year [7][8]. - The company's gross profit margin for 1H24 was 78.2%, reflecting a slight improvement from 77.7% in 1H23 [7]. - The projected earnings per share (EPS) for 2024E is RMB 0.63, with a slight increase of 6% from previous estimates [9][10]. Revenue and Profit Forecasts - The revenue forecast for 2024E is adjusted to RMB 2.982 billion, down 18% from previous estimates, while the net profit forecast is increased to RMB 1.048 billion, up 6% [9][10]. - The company’s product segments show varied performance, with biological products expected to generate RMB 2.133 billion in revenue for 2024E, down 23% from previous estimates [11][12]. Valuation - The report employs a two-stage DCF valuation method, resulting in a target price of RMB 10.78, which corresponds to a P/E ratio of 16 for 2025, higher than the average of comparable companies [12][15]. - The report notes that the company’s continuous growth in biological products justifies a premium valuation [12][15].
安科生物:多板块协同业绩韧性较强,中成药板块表现亮眼,研发稳健推进
GOLDEN SUN SECURITIES· 2024-09-03 02:10
Investment Rating - The report maintains a "Buy" rating for the company [3][5]. Core Views - The company demonstrated strong resilience in performance despite macroeconomic pressures, achieving revenue and profit growth in the first half of 2024 [2]. - The Chinese medicine segment showed significant growth, driving overall performance, with a 20.17% increase in revenue from traditional Chinese medicine [2]. - The company is focused on its strategic goals and core business, enhancing its competitive advantages and steadily advancing its operations [2]. Financial Performance - In H1 2024, the company achieved total revenue of 1.299 billion yuan (up 0.9% year-on-year) and a net profit attributable to shareholders of 416 million yuan (up 4.99%) [1]. - The revenue breakdown for H1 2024 includes: - Bioproducts: 902 million yuan (down 2.60%) - Traditional Chinese medicine: 199 million yuan (up 20.17%) - Chemical synthesis drugs: 81 million yuan (down 15.50%) - Raw materials: 61 million yuan (up 15.56%) - Technical services: 19 million yuan (up 71.41%) [2]. - The company's gross margin improved to 78.25%, an increase of 0.5 percentage points year-on-year [2]. R&D Progress - The company is actively advancing its R&D efforts, with several key projects: 1. The self-developed AK2017 is progressing smoothly in Phase II clinical trials. 2. A recombinant anti-VEGF humanized monoclonal antibody has completed Phase III clinical trials and is nearing market launch. 3. Collaboration with Shanghai Shijian Biotechnology for ADC platform technology licensing to enhance its innovative drug development [2]. - The company has received clinical trial approvals for multiple products, including an mRNA vaccine for respiratory syncytial virus and a treatment for HPV tumors [2]. Profit Forecast - The company is projected to achieve net profits of 906 million yuan, 1.072 billion yuan, and 1.254 billion yuan for the years 2024, 2025, and 2026, respectively, with corresponding growth rates of 6.9%, 18.4%, and 17.0% [3].
安科生物:业绩整体稳定,研发创新持续深入
SINOLINK SECURITIES· 2024-08-28 03:12
安科生物 (300009.SZ) 买入(维持评级) 证券研究报告 业绩简评 2024 年 8 月 27 日,公司发布 2024 年半年度报告,2024 年上半年 公司实现营业收入 12.99 亿元,同比增长 0.90%;实现归母净利润 4.16 亿元,同比增长 4.99%;实现扣非归母净利润 3.90 亿元,同 比增长 1.86%。分季度看,2024 年第二季度公司实现营业收入 6.43 亿元,同比减少 7.27%;实现归母净利润 1.98 亿元,同比减少 5.86%;实现扣非归母净利润 1.85 亿元,同比减少 9.58%。 经营分析 经营业绩整体稳定,中成药收入快速增长。公司坚定战略目标, 聚焦主业厚植优势,加强新质生产力建设,强化精益管理,进一 步夯实经营基础,推动公司业务稳步发展,提升公司高质量发展 核心竞争力。中成药子公司余良卿遵循以现代科技发展传统中药 的思路,在止痛领域,利用透皮吸收给药技术,升级传统中药贴 膏,研究开发新型化药贴膏;在中药大健康领域,深入挖掘现有 产品潜力,开发新产品,积极推进中药经典名方的研发,持续提 升公司价值。上半年公司中成药板块实现营业收入 1.99 亿元,同 比增长 ...
安科生物:2024年半年度非经营性资金占用及其他关联资金往来情况汇总表
2024-08-27 11:44
安徽安科生物工程(集团)股份有限公司 2024 年 6 月非经营性资金占用及其他关联资金往来情况汇总表 编制单位:安徽安科生物工程(集团)股份有限公司 单位:元 1 / 2 非经营性资金 占用 资金占用方名称 占用方与上市公 司的关联关系 上市公司核算 的会计科目 2024 年初占用 资金余额 2024 年 1-6 月占 用累计发生金额 (不含利息) 2024 年 1-6 月 占用资金的 利息(如有) 2024 年 1-6 月偿 还累计发生金额 2024年6月末 占用资金余 额 占用形成 原因 占用性 质 控股股东、实际 控制人及其附 属企业 - - - 小计 — — — - - - - 前控股股东、实 际控制人及其 附属企业 - - - 小计 — — — - - - - - 总计 — — — - - - - - | 其他关联资金 | | 往来方与上市公 | 上市公司核算 | 2024 年初往来 | 2024 年 1-6 | 月往 | 2024 年 | 1-6 月 | 2024 年 1-6 | 月偿 | 2024年6月末 | 往来形成 | 往来性 | | --- | --- | --- | --- | --- ...
安科生物(300009) - 2024 Q2 - 季度财报
2024-08-27 11:44
Financial Performance - The company's operating revenue for the first half of 2024 was approximately ¥1.30 billion, an increase of 0.90% compared to the same period last year[12]. - Net profit attributable to shareholders was approximately ¥416.13 million, reflecting a growth of 4.99% year-over-year[12]. - The net profit after deducting non-recurring gains and losses was approximately ¥390.20 million, up by 1.86% from the previous year[12]. - Basic and diluted earnings per share increased to ¥0.2482, representing a growth of 4.77%[12]. - Total assets at the end of the reporting period were approximately ¥4.84 billion, a decrease of 2.14% from the end of the previous year[12]. - The company's weighted average return on equity was 10.71%, down by 1.34% compared to the previous year[12]. - The total profit reached 492.02 million yuan, reflecting a year-on-year growth of 6.15%[28]. - The company achieved operating revenue of 1,298.82 million yuan, a year-on-year increase of 0.90%[28]. - The net cash flow from operating activities decreased by 38.18% to approximately ¥205.81 million[12]. - The company reported a total comprehensive income of ¥416,132,684.80 for the first half of 2024, reflecting a stable performance compared to the previous year[133]. Research and Development - The company is actively developing multiple new drug research projects, including monoclonal antibodies, bispecific antibodies, and innovative ADC drugs, to enhance its product pipeline[19]. - The company is committed to continuous R&D efforts, particularly in peptide-based therapies, to enhance its product pipeline and market competitiveness[24]. - The company is focused on expanding its market presence through strategic investments and collaborations, aiming for a robust growth trajectory[24]. - The company is advancing the construction of new production lines, including a 5000L fermentation tank for growth hormone, which is currently undergoing process validation[29]. - The company is actively pursuing clinical trials for multiple products, including the AK2017 injection and human interferon α2b spray, with several projects in various stages of development[30]. - The company is committed to deepening cooperation in the mRNA drug sector and is preparing for the launch of emerging gene therapy products[31]. - The company is exploring the development of new products and technologies to meet evolving market demands and improve patient outcomes[24]. - The company has a strong focus on R&D, with a well-established system and successful experience in the independent development and industrialization of multiple new drugs[37]. Corporate Governance and Compliance - The company has a comprehensive governance structure, including a board of directors and supervisory board, all of whom attended the meeting to review the semi-annual report[1]. - The company’s legal representative is Song Lihua, ensuring accountability for the accuracy of the financial report[7]. - The company emphasizes the importance of rational investment and risk awareness for investors regarding forward-looking statements[1]. - The company has not reported any changes in its registered address or contact information during the reporting period[9]. - The company maintains a commitment to transparency in its financial disclosures, with no changes in the locations for information disclosure during the reporting period[10]. - The company has not engaged in any significant related party transactions during the reporting period[92]. - The half-year financial report has not been audited, and there are no significant guarantees or major contracts reported[88][99]. Market and Industry Position - The biopharmaceutical industry is experiencing rapid growth, driven by strong demand and supportive government policies[16]. - The company is actively pursuing international expansion and innovation in biopharmaceuticals, aligning with national strategic initiatives[17]. - The company has been recognized with multiple national and provincial awards for its contributions to biotechnology and innovation[18]. - The company has positioned itself at the forefront of the biopharmaceutical industry, with its recombinant human growth hormone and interferon products leading in market share and brand advantage[37]. Environmental Responsibility - The company has invested over 28 million RMB in environmental governance and protection in the first half of 2024[84]. - The company has completed the environmental emergency response plan, which has been filed with the relevant environmental protection bureau, enhancing its emergency response capabilities[82]. - The company has reported zero instances of exceeding emission standards for wastewater and waste gas treatment facilities[81]. - The company has allocated approximately 146 million RMB for hazardous waste and wastewater treatment, as well as environmental protection equipment[82]. - Anke Biological achieved wastewater treatment compliance with COD at 84 mg/L, significantly below the standard of 350 mg/L, resulting in a reduction of 17.15 tons[78]. Shareholder and Capital Management - The company plans not to distribute cash dividends or issue bonus shares, nor will it increase capital through reserves[2]. - The company distributed a total cash dividend of ¥418,039,838.00 (including tax), accounting for 49.34% of the net profit attributable to shareholders for the year 2023[68]. - The company has maintained a continuous cash dividend for 15 years, with cumulative cash dividends exceeding 22.45 billion RMB, representing 63.27% of the net profit attributable to shareholders[84]. - The company’s major shareholders committed to not reducing their holdings for a period of six months starting from August 23, 2023[87]. - The company has a projected return of 21.41 million from a wealth management product with a duration of 70 days[54]. Strategic Initiatives - The company is focusing on improving operational efficiency and reducing production costs to adapt to the pressures of centralized procurement policies[63]. - The company is enhancing its investor relations management through multiple channels and platforms[68]. - The company is committed to continuous innovation and product development based on market demand and technological advancements[37]. - The company plans to focus on its core business and increase R&D investment to drive high-quality development[68]. - The company is actively advancing the construction of new facilities in the eastern region to meet market demand[68].
安科生物:监事会决议公告
2024-08-27 11:44
证券代码:300009 证券简称:安科生物 公告编号:2024-041 安徽安科生物工程(集团)股份有限公司 关于第八届监事会第十一次会议决议的公告 本公司及监事会全体成员保证公告内容真实、准确和完整,没有虚假记载、 误导性陈述或者重大遗漏。 安徽安科生物工程(集团)股份有限公司(以下简称"公司")第八届监事 会第十一次会议于 2024 年 8 月 16 日以书面形式发出会议通知,2024 年 8 月 26 日上午 11:00 以现场会议的方式召开。应参会监事 3 人,实际参会监事 3 人。本 次会议的召开与表决程序符合《公司法》和《公司章程》等的有关规定,会议由 监事会主席李增礼先生主持。 经与会监事充分讨论,表决通过如下决议: 一、以 3 票赞成,0 票反对,0 票弃权审议通过了《<公司 2024 年半年度报 告>及其摘要》 公司监事会根据《证券法》第八十二条的规定和中国证监会、深圳证券交易 所有关规定的要求,对公司 2024 年半年度报告及其摘要进行了认真审核,并提 出如下书面审核意见: 经审核,监事会认为董事会编制和审核公司 2024 年半年度报告的程序符合 法律、行政法规和中国证监会的规定,报告内容 ...